DaVita Inc. (DVA) Price/FCF Ratio: 9.63
Is DaVita Inc.’s Price/FCF ratio high or low?
DaVita Inc.'s Price/FCF ratio of 9.63 is in line with its 5-year average of 8.76, around the middle of its 5-year range (5.04–14.45).
20.26% above its 12-month average of 8.01.
DVA Price/FCF Ratio Chart
DVA Average Price/FCF Ratio Chart
DVA Current vs Average Price/FCF Ratio Chart
DVA Price/FCF Ratio Metrics
PRICE/FCF RATIO
9.63
PRICE/FCF RATIO AVG TTM
8.01
PRICE/FCF RATIO AVG 3Y
8.71
PRICE/FCF RATIO AVG 5Y
8.75
PRICE/FCF RATIO AVG 10Y
9.81
PRICE/FCF RATIO AVG 15Y
11.45
PRICE/FCF RATIO AVG 20Y
13.90
CURRENT VS TTM AVG
+20.26%
CURRENT VS 3Y AVG
+10.53%
CURRENT VS 5Y AVG
+10.01%
CURRENT VS 10Y AVG
-1.82%
CURRENT VS 15Y AVG
-15.91%
CURRENT VS 20Y AVG
-30.71%
DVA Competitors' Price/FCF Ratio
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DaVita Inc. (DVA) | $13.40B | 9.63 | 8.01 | 8.71 | 8.75 |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 23.24 | 34.01 | 71.59 | 58.03 |
| Solventum Corporation (SOLV)vs › | $13.66B | N/A | 116.92 | 65.01 | 65.01 |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 18.25 | 19.09 | 31.10 | 40.51 |
| Baxter International Inc. (BAX)vs › | $10.77B | 15.05 | 39.59 | 31.00 | 30.29 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 17.86 | 17.13 | 29.64 | 17.62 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 17.18 | 16.15 | 18.18 | 14.60 |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 23.46 | 16.28 | 22.79 | 28.32 |
| Tempus AI, Inc. (TEM)vs › | $8.35B | N/A | N/A | N/A | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 21.58 | 22.32 | 39.24 | 47.55 |
Free Cash Flow Valuation
P/FCF Ratio
9.6
FCF Yield
10.38%
DaVita Inc. Price/FCF Ratio Formula & Definition
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DaVita Inc. Price/FCF Ratio FAQ
- What is the Price/FCF ratio for DaVita Inc. (DVA)?
- The Price/FCF ratio for DVA stock is 9.63.
- Is DaVita Inc.'s Price/FCF ratio high or low?
- DaVita Inc.'s Price/FCF ratio of 9.63 is in line with its 5-year average of 8.76, around the middle of its 5-year range (5.04–14.45).
- What is the TTM average Price/FCF ratio for DaVita Inc. (DVA)?
- The TTM average Price/FCF ratio for DVA stock is 8.01.
- What is the 3Y average Price/FCF ratio for DaVita Inc. (DVA)?
- The 3Y average Price/FCF ratio for DVA stock is 8.71.
- What is the 5Y average Price/FCF ratio for DaVita Inc. (DVA)?
- The 5Y average Price/FCF ratio for DVA stock is 8.75.
- What is the 10Y average Price/FCF ratio for DaVita Inc. (DVA)?
- The 10Y average Price/FCF ratio for DVA stock is 9.81.
- What is the 15Y average Price/FCF ratio for DaVita Inc. (DVA)?
- The 15Y average Price/FCF ratio for DVA stock is 11.45.
- What is the 20Y average Price/FCF ratio for DaVita Inc. (DVA)?
- The 20Y average Price/FCF ratio for DVA stock is 13.90.
DaVita Inc. Price/FCF Ratio History
| DATE | PRICE/FCF RATIO |
|---|---|
| 2026-06-12 | 9.63 |
| 2026-06-11 | 9.40 |
| 2026-06-10 | 9.16 |
| 2026-06-09 | 9.14 |
| 2026-06-08 | 8.86 |
| 2026-06-05 | 8.87 |
| 2026-06-04 | 8.87 |
| 2026-06-03 | 9.00 |
| 2026-06-02 | 8.67 |
| 2026-06-01 | 8.76 |
| 2026-05-29 | 8.97 |
| 2026-05-28 | 9.09 |
| 2026-05-27 | 8.99 |
| 2026-05-26 | 9.02 |
| 2026-05-22 | 9.16 |
| 2026-05-21 | 9.17 |
| 2026-05-20 | 9.08 |
| 2026-05-19 | 8.98 |
| 2026-05-18 | 9.21 |
| 2026-05-15 | 9.22 |
| 2026-05-14 | 8.89 |
| 2026-05-13 | 9.14 |
| 2026-05-12 | 9.25 |
| 2026-05-11 | 9.18 |
| 2026-05-08 | 9.17 |
| 2026-05-07 | 9.06 |
| 2026-05-06 | 8.95 |
| 2026-05-05 | 7.25 |
| 2026-05-04 | 10.36 |
| 2026-05-01 | 10.19 |
| 2026-04-30 | 10.43 |
| 2026-04-29 | 10.22 |
| 2026-04-28 | 10.09 |
| 2026-04-27 | 10.09 |
| 2026-04-24 | 10.21 |
| 2026-04-23 | 10.42 |
| 2026-04-22 | 10.25 |
| 2026-04-21 | 10.08 |
| 2026-04-20 | 10.04 |
| 2026-04-17 | 9.94 |
| 2026-04-16 | 9.96 |
| 2026-04-15 | 9.72 |
| 2026-04-14 | 10.05 |
| 2026-04-13 | 10.19 |
| 2026-04-10 | 10.09 |
| 2026-04-09 | 10.13 |
| 2026-04-08 | 9.98 |
| 2026-04-07 | 10.06 |
| 2026-04-06 | 10.09 |
| 2026-04-02 | 9.79 |
| 2026-04-01 | 10.11 |
| 2026-03-31 | 10.33 |
| 2026-03-30 | 10.24 |
| 2026-03-27 | 10.38 |
| 2026-03-26 | 10.54 |
| 2026-03-25 | 10.43 |
| 2026-03-24 | 10.30 |
| 2026-03-23 | 10.23 |
| 2026-03-20 | 10.04 |
| 2026-03-19 | 10.07 |
| 2026-03-18 | 10.00 |
| 2026-03-17 | 10.08 |
| 2026-03-16 | 9.96 |
| 2026-03-13 | 10.13 |
| 2026-03-12 | 10.29 |
| 2026-03-11 | 10.41 |
| 2026-03-10 | 10.19 |
| 2026-03-09 | 10.25 |
| 2026-03-06 | 10.13 |
| 2026-03-05 | 10.08 |
| 2026-03-04 | 10.40 |
| 2026-03-03 | 10.24 |
| 2026-03-02 | 10.35 |
| 2026-02-27 | 10.51 |
| 2026-02-26 | 10.25 |
| 2026-02-25 | 10.05 |
| 2026-02-24 | 10.14 |
| 2026-02-23 | 10.17 |
| 2026-02-20 | 10.13 |
| 2026-02-19 | 9.90 |
| 2026-02-18 | 9.93 |
| 2026-02-17 | 10.11 |
| 2026-02-13 | 10.01 |
| 2026-02-12 | 10.08 |
| 2026-02-11 | 9.70 |
| 2026-02-10 | 7.95 |
| 2026-02-09 | 7.86 |
| 2026-02-06 | 8.04 |
| 2026-02-05 | 8.52 |
| 2026-02-04 | 8.11 |
| 2026-02-03 | 7.69 |
| 2026-02-02 | 6.35 |
| 2026-01-30 | 6.24 |
| 2026-01-29 | 6.12 |
| 2026-01-28 | 6.04 |
| 2026-01-27 | 6.03 |
| 2026-01-26 | 6.14 |
| 2026-01-23 | 6.17 |
| 2026-01-22 | 6.23 |
| 2026-01-21 | 6.07 |
| 2026-01-20 | 5.93 |
| 2026-01-16 | 5.98 |
| 2026-01-15 | 6.04 |
| 2026-01-14 | 5.93 |
| 2026-01-13 | 5.96 |
| 2026-01-12 | 6.28 |
| 2026-01-09 | 6.36 |
| 2026-01-08 | 6.43 |
| 2026-01-07 | 6.34 |
| 2026-01-06 | 6.55 |
| 2026-01-05 | 6.50 |
| 2026-01-02 | 6.54 |
| 2025-12-31 | 6.49 |
| 2025-12-30 | 6.50 |
| 2025-12-29 | 6.48 |
| 2025-12-26 | 6.51 |
| 2025-12-24 | 6.53 |
| 2025-12-23 | 6.55 |
| 2025-12-22 | 6.65 |
| 2025-12-19 | 6.58 |
| 2025-12-18 | 6.63 |
| 2025-12-17 | 6.76 |
| 2025-12-16 | 6.73 |
| 2025-12-15 | 6.85 |
| 2025-12-12 | 6.93 |
| 2025-12-11 | 6.87 |
| 2025-12-10 | 6.77 |
| 2025-12-09 | 6.66 |
| 2025-12-08 | 6.68 |
| 2025-12-05 | 6.70 |
| 2025-12-04 | 6.69 |
| 2025-12-03 | 6.75 |
| 2025-12-02 | 6.80 |
| 2025-12-01 | 6.81 |
| 2025-11-28 | 6.83 |
| 2025-11-26 | 6.86 |
| 2025-11-25 | 6.93 |
| 2025-11-24 | 6.82 |
| 2025-11-21 | 6.86 |
| 2025-11-20 | 6.58 |
| 2025-11-19 | 6.58 |
| 2025-11-18 | 6.65 |
| 2025-11-17 | 6.69 |
| 2025-11-14 | 6.94 |
| 2025-11-13 | 7.02 |
| 2025-11-12 | 7.06 |
| 2025-11-11 | 6.98 |
| 2025-11-10 | 6.86 |
| 2025-11-07 | 7.06 |
| 2025-11-06 | 6.94 |
| 2025-11-05 | 6.92 |
| 2025-11-04 | 6.85 |
| 2025-11-03 | 6.80 |
| 2025-10-31 | 6.79 |
| 2025-10-30 | 6.78 |
| 2025-10-29 | 7.22 |
| 2025-10-28 | 7.78 |
| 2025-10-27 | 7.78 |
| 2025-10-24 | 7.76 |
| 2025-10-23 | 7.69 |
| 2025-10-22 | 7.75 |
| 2025-10-21 | 7.71 |
| 2025-10-20 | 7.69 |
| 2025-10-17 | 7.56 |
| 2025-10-16 | 7.52 |
| 2025-10-15 | 7.57 |
| 2025-10-14 | 7.60 |
| 2025-10-13 | 7.44 |
| 2025-10-10 | 7.45 |
| 2025-10-09 | 7.59 |
| 2025-10-08 | 7.68 |
| 2025-10-07 | 7.87 |
| 2025-10-06 | 7.69 |
| 2025-10-03 | 7.88 |
| 2025-10-02 | 7.93 |
| 2025-10-01 | 7.98 |
| 2025-09-30 | 7.98 |
| 2025-09-29 | 7.84 |
| 2025-09-26 | 7.85 |
| 2025-09-25 | 7.82 |
| 2025-09-24 | 8.02 |
| 2025-09-23 | 7.98 |
| 2025-09-22 | 7.88 |
| 2025-09-19 | 7.82 |
| 2025-09-18 | 7.82 |
| 2025-09-17 | 7.69 |
| 2025-09-16 | 7.81 |
| 2025-09-15 | 7.86 |
| 2025-09-12 | 8.00 |
| 2025-09-11 | 8.00 |
| 2025-09-10 | 7.94 |
| 2025-09-09 | 8.21 |
| 2025-09-08 | 8.08 |
| 2025-09-05 | 8.28 |
| 2025-09-04 | 8.14 |
| 2025-09-03 | 8.16 |
| 2025-09-02 | 8.22 |
| 2025-08-29 | 8.27 |
| 2025-08-28 | 8.17 |
| 2025-08-27 | 8.26 |
| 2025-08-26 | 8.33 |
| 2025-08-25 | 8.25 |
| 2025-08-22 | 8.43 |
| 2025-08-21 | 8.26 |
| 2025-08-20 | 8.25 |
| 2025-08-19 | 8.21 |
| 2025-08-18 | 8.00 |
| 2025-08-15 | 8.13 |
| 2025-08-14 | 8.07 |
| 2025-08-13 | 8.09 |
| 2025-08-12 | 7.93 |
| 2025-08-11 | 7.75 |
| 2025-08-08 | 7.78 |
| 2025-08-07 | 7.67 |
| 2025-08-06 | 7.67 |
| 2025-08-05 | 8.44 |
| 2025-08-04 | 6.45 |
| 2025-08-01 | 6.40 |
| 2025-07-31 | 6.49 |
| 2025-07-30 | 6.68 |
| 2025-07-29 | 6.74 |
| 2025-07-28 | 6.71 |
| 2025-07-25 | 6.71 |
| 2025-07-24 | 6.69 |
| 2025-07-23 | 6.99 |
| 2025-07-22 | 6.75 |
| 2025-07-21 | 6.44 |
| 2025-07-18 | 6.52 |
| 2025-07-17 | 6.62 |
| 2025-07-16 | 6.48 |
| 2025-07-15 | 6.49 |
| 2025-07-14 | 6.63 |
| 2025-07-11 | 6.59 |
| 2025-07-10 | 6.63 |
| 2025-07-09 | 6.55 |
| 2025-07-08 | 6.64 |
| 2025-07-07 | 6.60 |
| 2025-07-03 | 6.59 |
| 2025-07-02 | 6.59 |
| 2025-07-01 | 6.78 |
| 2025-06-30 | 6.58 |
| 2025-06-27 | 6.55 |
| 2025-06-26 | 6.52 |
| 2025-06-25 | 6.48 |
| 2025-06-24 | 6.51 |
| 2025-06-23 | 6.30 |
| 2025-06-20 | 6.33 |
| 2025-06-18 | 6.27 |
| 2025-06-17 | 6.31 |
| 2025-06-16 | 6.37 |
| 2025-06-13 | 6.29 |
| 2025-06-12 | 6.35 |
| 2025-06-11 | 6.38 |
| 2025-06-10 | 6.43 |
| 2025-06-09 | 6.37 |
| 2025-06-06 | 6.37 |
| 2025-06-05 | 6.36 |
| 2025-06-04 | 6.32 |
| 2025-06-03 | 6.28 |
| 2025-06-02 | 6.21 |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez